Cover Image
市場調查報告書

Immune Pharmaceuticals, Inc. - 產品平台分析

Immune Pharmaceuticals Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 253709
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
Immune Pharmaceuticals, Inc. - 產品平台分析 Immune Pharmaceuticals Inc. - Product Pipeline Review - 2016
出版日期: 2016年07月27日 內容資訊: 英文 61 Pages
簡介

Immune Pharmaceuticals, Inc.是開發發炎性疾病及癌症治療用單株抗體,並上市的生物製藥公司。

本報告提供Immune Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Immune Pharmaceuticals, Inc.的基本資料

  • Immune Pharmaceuticals, Inc.概要
  • 主要資訊
  • 企業資料

Immune Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Immune Pharmaceuticals Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 聯合治療模式
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Immune Pharmaceuticals Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
  • IND/CTA 被申請了的產品/聯合治療模式
    • 前臨床階段的產品/聯合治療模式

Immune Pharmaceuticals Inc.:藥物簡介

  • (amitriptyline + ketamine hydrochloride)
  • bertilimumab
  • crolibulin
  • lidocaine hydrochloride
  • F-573
  • Ferritizumab
  • Monoclonal Antibody Conjugate for Non-Small Cell Lung Cancer and Pancreatic Cancer
  • Monoclonal Antibody Conjugate to Antagonize EGFR for Non-Small Cell Lung Cancer
  • Monoclonal Antibody Conjugate to Antagonize HER2 for Solid Tumors
  • Monoclonal Antibody Conjugate to Antagonize HER3 for Solid Tumors

Immune Pharmaceuticals Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Immune Pharmaceuticals Inc.:最近的開發平台趨勢

Immune Pharmaceuticals Inc.:暫停中的計劃

Immune Pharmaceuticals Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • histamine dihydrochloride
    • verubulin

Immune Pharmaceuticals Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08099CDB

Summary

Global Markets Direct's, 'Immune Pharmaceuticals Inc. - Product Pipeline Review, 2016', provides an overview of the Immune Pharmaceuticals Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Immune Pharmaceuticals Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Immune Pharmaceuticals Inc.
  • The report provides overview of Immune Pharmaceuticals Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Immune Pharmaceuticals Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Immune Pharmaceuticals Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Immune Pharmaceuticals Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Immune Pharmaceuticals Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Immune Pharmaceuticals Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Immune Pharmaceuticals Inc. Snapshot
    • Immune Pharmaceuticals Inc. Overview
    • Key Information
    • Key Facts
  • Immune Pharmaceuticals Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Immune Pharmaceuticals Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Immune Pharmaceuticals Inc. - Pipeline Products Glance
    • Immune Pharmaceuticals Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Immune Pharmaceuticals Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Immune Pharmaceuticals Inc. - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • Immune Pharmaceuticals Inc. - Drug Profiles
    • histamine dihydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (amitriptyline + ketamine hydrochloride)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bertilimumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • crolibulin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lidocaine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • F-573
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Ferritizumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Target HLA-DR and CD5 for Leukemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate for Non-Small Cell Lung Cancer and Pancreatic Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target EGFR for Non-Small Cell Lung Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target HER2 for Metastatic Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Target HER3 for Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • verubulin
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Immune Pharmaceuticals Inc. - Pipeline Analysis
    • Immune Pharmaceuticals Inc. - Pipeline Products by Target
    • Immune Pharmaceuticals Inc. - Pipeline Products by Route of Administration
    • Immune Pharmaceuticals Inc. - Pipeline Products by Molecule Type
    • Immune Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action
  • Immune Pharmaceuticals Inc. - Recent Pipeline Updates
  • Immune Pharmaceuticals Inc. - Dormant Projects
  • Immune Pharmaceuticals Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • histamine dihydrochloride
      • verubulin
  • Immune Pharmaceuticals Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Immune Pharmaceuticals Inc., Key Information
  • Immune Pharmaceuticals Inc., Key Facts
  • Immune Pharmaceuticals Inc. - Pipeline by Indication, 2016
  • Immune Pharmaceuticals Inc. - Pipeline by Stage of Development, 2016
  • Immune Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2016
  • Immune Pharmaceuticals Inc. - Combination Treatment Modalities in Pipeline, 2016
  • Immune Pharmaceuticals Inc. - Partnered Products in Pipeline, 2016
  • Immune Pharmaceuticals Inc. - Partnered Products/ Combination Treatment Modalities, 2016
  • Immune Pharmaceuticals Inc. - Phase III, 2016
  • Immune Pharmaceuticals Inc. - Phase II, 2016
  • Immune Pharmaceuticals Inc. - Phase I, 2016
  • Immune Pharmaceuticals Inc. - IND/CTA Filed, 2016
  • Immune Pharmaceuticals Inc. - Preclinical, 2016
  • Immune Pharmaceuticals Inc. - Pipeline by Target, 2016
  • Immune Pharmaceuticals Inc. - Pipeline by Route of Administration, 2016
  • Immune Pharmaceuticals Inc. - Pipeline by Molecule Type, 2016
  • Immune Pharmaceuticals Inc. - Pipeline Products by Mechanism of Action, 2016
  • Immune Pharmaceuticals Inc. - Recent Pipeline Updates, 2016
  • Immune Pharmaceuticals Inc. - Dormant Developmental Projects,2016
  • Immune Pharmaceuticals Inc. - Discontinued Pipeline Products, 2016
  • Immune Pharmaceuticals Inc., Other Locations
  • Immune Pharmaceuticals Inc., Subsidiaries

List of Figures

  • Immune Pharmaceuticals Inc. - Pipeline by Top 10 Indication, 2016
  • Immune Pharmaceuticals Inc. - Pipeline by Stage of Development, 2016
  • Immune Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2016
  • Immune Pharmaceuticals Inc. - Partnered Products in Pipeline, 2016
  • Immune Pharmaceuticals Inc. - Pipeline by Top 10 Target, 2016
  • Immune Pharmaceuticals Inc. - Pipeline by Route of Administration, 2016
  • Immune Pharmaceuticals Inc. - Pipeline by Molecule Type, 2016
  • Immune Pharmaceuticals Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top